Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9961325 | 0.77 | LMNA (0.37) | LMNAPDK2 | |
| SCHEMBL22337370 | 0.67 | CYP1A2 (0.43) | KCNH2PIM1PIM3PIM2 | |
| SCHEMBL21103826 | 0.66 | GRM4 (0.33) | PIM1PIM3PIM2 | |
| SCHEMBL22338015 | 0.65 | CYP1A2 (0.45) | LMNA | |
| SCHEMBL360968 | 0.65 | — | — | |
| SCHEMBL2360040 | 0.65 | — | — | |
| SCHEMBL2442999 | 0.64 | LMNA (0.31) | LMNA | |
| SCHEMBL13534125 | 0.64 | EGFR (0.40) | LMNA | |
| SCHEMBL16544066 | 0.64 | KDM4E (0.32) | — | |
| SCHEMBL11985810 | 0.64 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897886-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2024-02-13 | — | — | US | disclosed |
| US-20210246141-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2021-08-12 | — | — | US | disclosed |
| US-10858361-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200255431-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-08-13 | — | — | US | disclosed |
| US-10689386-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190276457-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2019-09-12 | — | — | US | disclosed |
| US-20080234381-A1 | Novel Trifluoromethoxy-Substituted Aryl Anilides | NOVO NORDISK A/S (DK) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897886-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | RB1, RRM2, RRM2B | LMNA 3789/4885KCNH2 940/4885PIM1 2784/4885 |
| US-10858361-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | RB1, RRM2, RRM2B | LMNA 3789/4885KCNH2 940/4885PIM1 2784/4885 |
| US-20210246141-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | RB1, RRM2, RRM2B | LMNA 3789/4885KCNH2 940/4885PIM1 2784/4885 |
| US-20190276457-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DPYD, TP53, TYMP | LMNA 4282/4885KCNH2 483/4885PIM1 2660/4885 |
| US-10689386-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DPYD, TP53, TYMP | LMNA 4282/4885KCNH2 483/4885PIM1 2660/4885 |
| US-20200255431-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | RB1, RRM2, RRM2B | LMNA 3789/4885KCNH2 940/4885PIM1 2784/4885 |
| US-20080234381-A1 | Novel Trifluoromethoxy-Substituted Aryl Anilides | GPR119, FABP4, TFAM | LMNA 4131/4885KCNH2 3081/4885PIM1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.